📣 VC round data is live. Check it out!
- Public Comps
- LivaNova
LivaNova Valuation Multiples
Discover LivaNova's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Jiangsu Yuyue Medical, Ottobock, Envista Holdings, BillionToOne and more.
LivaNova Overview
About LivaNova
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Founded
2015
HQ

Employees
2.9K
Website
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialLivaNova Financials
LivaNova reported last 12-month revenue of $1B and EBITDA of $332M.
In the same LTM period, LivaNova generated $984M in gross profit, $332M in EBITDA, and $225M in net income.
Revenue (LTM)
LivaNova P&L
In the most recent fiscal year, LivaNova reported revenue of $1B and EBITDA of $317M.
LivaNova is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 23%, and net margin of 15%.
Financial data powered by Morningstar, Inc.
LivaNova Stock Performance
LivaNova has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
LivaNova's stock price is $73.33.
LivaNova share price decreased by 0.7% in the last 30 days, and increased by 62.9% in the last year.
LivaNova has an EPS (earnings per share) of $3.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -0.7% | -0.7% | 15.4% | 62.9% | $3.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLivaNova Valuation Multiples
LivaNova trades at 2.7x EV/Revenue multiple, and 11.6x EV/EBITDA.
EV / Revenue (LTM)
LivaNova Financial Valuation Multiples
As of June 4, 2026, LivaNova has market cap of $4B and EV of $4B.
LivaNova has a P/E ratio of 17.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified LivaNova Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


LivaNova Margins & Growth Rates
LivaNova grew revenue by 9% and EBITDA by 11% in the last fiscal year.
In the most recent fiscal year, LivaNova reported gross margin of 68%, EBITDA margin of 23%, and net margin of 15%.
LivaNova Margins
LivaNova Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
LivaNova Operational KPIs
LivaNova's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
LivaNova's Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LivaNova's Rule of X is 45% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
LivaNova Competitors
LivaNova competitors include Jiangsu Yuyue Medical, Ottobock, Envista Holdings, BillionToOne, APT Medical, Mirion, Merit Medical Systems, Imeik Technology Development, Cochlear and iRhythm Holdings.
Most LivaNova public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.3x | 3.2x | 13.3x | 16.2x | |||
| 2.8x | 2.7x | 15.2x | 10.6x | |||
| 1.6x | 1.5x | 11.4x | 11.0x | |||
| 12.9x | 10.7x | 105.5x | 67.9x | |||
| 10.9x | 9.9x | 26.8x | 25.0x | |||
| 5.7x | 5.2x | 23.0x | 20.6x | |||
| 2.6x | 2.5x | 10.4x | 10.2x | |||
| 11.0x | 10.6x | 17.1x | 17.8x | |||
This data is available for Pro users. Sign up to see all LivaNova competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by LivaNova
LivaNova has acquired 5 companies to date.
Last acquisition by LivaNova was on May 2nd 2022. LivaNova acquired ALung Technologies for $113M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by LivaNova
| Description | ALung Technologies is a Pittsburgh-headquartered medical device company founded in 1997, specializing in extracorporeal gas exchange for acute respiratory failure. Its Hemolung RAS device, a minimally invasive catheter-based system, removes CO2 from blood via percutaneous femoral vein insertion, approved in Europe and used in over 500 ICU patients worldwide. | TandemLife is a medical device company manufacturing circulatory support systems for cardiologists and surgeons. Pittsburgh-headquartered, its FDA-cleared TandemHeart platform delivers up to 5 liters per minute percutaneously or 8 liters surgically via left atrial cannulation. Used in cath labs and ORs worldwide, the system includes pump, cannulae, and controllers with auto-monitoring. Acquired by LivaNova in 2018, TandemLife supports over 10,000 procedures annually in heart failure cases. | ImThera Medical is a San Diego-based medical device company developing neurostimulation implants for obstructive sleep apnea. Its THN Sleep Therapy System stimulates hypoglossal nerve branches to tone tongue muscles during sleep, reducing airway collapse events. The implantable device pairs with an external programmer for therapy adjustments. Founded in 2008, ImThera completed first-in-human trials in Europe and prepares for FDA pivotal studies, targeting the 28 million U.S. OSA patients non-compliant with CPAP. | Seattle-based Caisson Interventional develops percutaneous mitral valve replacement devices for treating severe mitral regurgitation. Its TMVr system features a fully retrievable valve delivered via 32 Fr sheath, implanted in over 100 patients across US and EU trials. The technology received CE Mark in 2019 and FDA breakthrough designation. Acquired by Boston Scientific in 2021 for $425 million upfront. | |
| HQ Country | |||||
| HQ City | Pittsburgh, PA | Pittsburgh, PA | San Diego, CA | Minneapolis, MN | |
| Deal Date | 2 May 2022 | 14 Feb 2018 | 5 Dec 2017 | 2 May 2017 | |
| Valuation | $113M | $250M | $225M | $141M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all LivaNova acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by LivaNova
LivaNova has invested in 6 companies to date.
Latest investment by LivaNova was on February 28th 2023. LivaNova invested in Cadence Neuroscience in their $26M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by LivaNova
| Description | Cadence Neuroscience is a Redmond, Washington-headquartered medtech firm founded in 2017, developing implantable neurostimulation devices for epilepsy and chronic pain based on Mayo Clinic research. Its closed-loop brain stimulation system personalizes therapy parameters during surgery to optimize seizure control and pain relief, currently advancing through clinical trials. | Noctrix Health is a medical device company based in Plymouth, Minnesota, that commercializes the NX-Q foot stimulation device for restless legs syndrome treatment. Cleared by the FDA in 2021, the therapy delivers neuromuscular electrical stimulation during daytime to reduce RLS symptoms by 60 percent in clinical trials. Noctrix distributes through neurology clinics in the US and Europe. | ShiraTronics is a medtech company engineering implantable neuromodulation devices for chronic migraine treatment. Its platform delivers precise nerve stimulation via a minimally invasive auricular system, reducing headache frequency and severity. Minneapolis-headquartered, ShiraTronics advances clinical trials toward FDA clearance for patients unresponsive to conventional therapies. | CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal. | |
| HQ Country | |||||
| HQ City | Seattle, WA | San Francisco, CA | Minneapolis, MN | - | |
| Deal Date | 28 Feb 2023 | 11 Jan 2021 | 24 Oct 2019 | 25 Sep 2018 | |
| Round | Series B | Series B | Series A | Series B | |
| Raised | $26M | $17M | $42M | $35M | |
| Investors | Angelini Lumira Biosciences Fund; Angelini Ventures; F-Prime; Jazz Venture Partners; LivaNova; Mayo Clinic | LivaNova; OrbiMed; Treo Ventures | Amzak Health Investors; Aperture Venture Partners; LivaNova; Treo Ventures; U.S. Venture Partners | LivaNova; Optimas Capital Partners Fund; The Rise Fund; UCB | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all LivaNova investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout LivaNova
| When was LivaNova founded? | LivaNova was founded in 2015. |
| Where is LivaNova headquartered? | LivaNova is headquartered in United States. |
| How many employees does LivaNova have? | As of today, LivaNova has over 2K employees. |
| Who is the CEO of LivaNova? | LivaNova's CEO is Vladimir A. Makatsaria. |
| Is LivaNova publicly listed? | Yes, LivaNova is a public company listed on Nasdaq. |
| What is the stock symbol of LivaNova? | LivaNova trades under LIVN ticker. |
| When did LivaNova go public? | LivaNova went public in 1993. |
| Who are competitors of LivaNova? | LivaNova main competitors include Jiangsu Yuyue Medical, Ottobock, Envista Holdings, BillionToOne, APT Medical, Mirion, Merit Medical Systems, Imeik Technology Development, Cochlear, iRhythm Holdings. |
| What is the current market cap of LivaNova? | LivaNova's current market cap is $4B. |
| What is the current revenue of LivaNova? | LivaNova's last 12 months revenue is $1B. |
| What is the current revenue growth of LivaNova? | LivaNova revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of LivaNova? | Current revenue multiple of LivaNova is 2.7x. |
| What is the current EBITDA of LivaNova? | LivaNova's last 12 months EBITDA is $332M. |
| What is LivaNova's EBITDA margin? | LivaNova's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of LivaNova? | Current EBITDA multiple of LivaNova is 11.6x. |
| What is the current FCF of LivaNova? | LivaNova's last 12 months FCF is $174M. |
| What is LivaNova's FCF margin? | LivaNova's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of LivaNova? | Current FCF multiple of LivaNova is 22.0x. |
| How many companies LivaNova has acquired to date? | As of June 2026, LivaNova has acquired 5 companies. |
| What was the largest acquisition by LivaNova? | $3B acquisition of Cyberonics on 19th October 2015 was the largest M&A LivaNova has done to date. |
| What companies LivaNova acquired? | LivaNova acquired Cyberonics, TandemLife, ImThera Medical, Caisson Interventional, and ALung Technologies. |
| In how many companies LivaNova has invested to date? | As of June 2026, LivaNova has invested in 6 companies. |
| In what companies LivaNova invested in? | LivaNova invested in ShiraTronics, CeriBell, Cadence Neuroscience, Noctrix Health, HighLife, and MD Start. |
See public comps similar to LivaNova
Lists including LivaNova
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
